🇺🇸 FDA
Patent

US 9845346

Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

granted A61KA61K38/00A61K38/47

Quick answer

US patent 9845346 (Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof) held by BIOMARIN PHARMACEUTICAL INC. expires Mon Dec 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOMARIN PHARMACEUTICAL INC.
Grant date
Tue Dec 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K38/00, A61K38/47, A61P, A61P3/00